

**Mr. Iñigo de la Lastra**

Head of Secondary Markets  
Spanish Stock Exchange Commission  
Miguel Ángel, 11, 1st floor  
28010 Madrid

## RELEVANT FACT

Valencia (Spain) July 2nd, 2012

Dear Sir,

In accordance with Article 82 of Law 24/1988, 28th July, relative to the regulation of the stock market and related provisions, we hereby inform you that the Shareholders General Meeting was held upon the first call on June 28, 2012, with the established Agenda and shareholders present in 17.15% and represented in 53.47%, which headlined a combined 70.62% of the shares representing the capital.

All resolutions were adopted unanimously, except for items 3, 4 and 5 which were adopted unanimously by the shareholders present and a large majority of the shareholders represented, all in the following sense:

- I. It was approved the individual and consolidated financial statements as well as the board of directors' conduct of business for the year 2011.
- II. It was approved the allocation of the 2011 result against negative results from previous years, for their compensation with future years' profits.
- III. It was approved the Board of Directors' remuneration for 2012 in the amount of 150,000 €, equal to the previous year.
- IV. It was agreed to authorize the Board of Directors to carry out the derivative acquisition of treasury stock, either directly or via investee companies, with the limits and requirements established in the Public Limited Company Law, thus superseding the authorisation granted in the Shareholders Meeting of 23 June 2011.
- V. It was agreed to keep in seven the number of board members and also:

**Head Office:**

Pl. Xavier Cugat, 2, Ed. D, 2 B  
08174 St. Cugat del Vallès, Barcelona  
Spain  
Tel. (+34) 93 584 81 85  
Fax. (+34) 93 584 81 90

# natraceutical

\* Ratify as Director the entity IBERSUIZAS ALFA, SL, sole proprietorship, established in Madrid, Calle Marques de Villamagna, No. 3, entered in the Register of Madrid, Volume 14104, Book 0, Sheet 13, Section 8, Page M- 231.737 and VIT B-82294315.

\* Re-elect as Director for a period of five years from this date, the entity BMS PROMOCIÓN Y DESARROLLO, SL, established in Valencia, Avenida Menendez Pelayo, No. 1, door 10, entered in the Register of Valencia, volume 4976, Book 2284, sheet 221, section 8, page V-36 569, with VIT B96329354

\* Re-elect as Director, for a period of five years from this date, Mr. FELIX REVUELTA FERNANDEZ, adult, married, resident of Barcelona (Spain), established in Passage Pedro Rodriguez, No. 4, gate 6, and NIF No. 16483572-R.

\* Cease as Director CK CORPORACION KUTXA-KUTXA KORPORAZIOA, S.L.U. and appoint as Director, for a period of five years from this date, Ms. MARIA JESUS ARREGUI ARIJA, adult, single, resident of Donostia-San Sebastián (Spain), established in Calle Garibai , No. 15 and NIF No. 15984931-S.

VI. It empowered the Secretary of the Board of Directors for the development, documentation and implementation of the resolutions adopted by the General Meeting.

During the celebration of the Shareholders General Meeting, the Company advanced the operating results at the end of May 2012 of its subsidiary Forté Pharma, as was reflected in the presentation that the company submitted to the Spanish Stock Exchange Commission (CNMV) before the start of the Meeting. At May closing, the turnover of Forté Pharma stood at 15.23 million euros compared to 17.50 million euros in the same period last year, the EBITDA reached 2.19 million euros compared to 0.09 million euros in May 2011 and the operating income stood at 1.55 million euros compared to -0.64 million euros last year.

Natraceutical also informed about having reduced its debt in 9.53 million euros during the first five months of the year, in addition to the reduction of 27.14 million euros in 2011, which sets the net financial debt on May 31, 2012 in 47.79 million euros.

Yours faithfully,

M<sup>a</sup> José Busutil Santos  
Secretary of the Board of Directors  
Natraceutical, S.A.